276 related articles for article (PubMed ID: 31218271)
1. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.
Chung JH; Dewal N; Sokol E; Mathew P; Whitehead R; Millis SZ; Frampton GM; Bratslavsky G; Pal SK; Lee RJ; Necchi A; Gregg JP; Lara P; Antonarakis ES; Miller VA; Ross JS; Ali SM; Agarwal N
JCO Precis Oncol; 2019; 3():. PubMed ID: 31218271
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
[TBL] [Abstract][Full Text] [Related]
3. Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.
Necchi A; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Ross JS; Jacob JM
Eur Urol Focus; 2019 Sep; 5(5):748-755. PubMed ID: 31147264
[TBL] [Abstract][Full Text] [Related]
4. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Lin DI; Fine A; Danziger NA; Huang RSP; Mata DA; Decker B; Killian JK; Ramkissoon SH; Lechpammer M; Janovitz T; Ross JS; Sokol ES; Elvin JA
Gynecol Oncol; 2022 Mar; 164(3):558-565. PubMed ID: 34998597
[TBL] [Abstract][Full Text] [Related]
6. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibitor Insensitivity to
Sokol ES; Jin DX; Fine A; Trabucco SE; Maund S; Frampton G; Molinero L; Antonarakis ES
JCO Precis Oncol; 2022 Jun; 6():e2100531. PubMed ID: 35772050
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
9. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma.
Bustamante B; Sinha R; Rice B; Nizam A; Shan W; Goldberg GL; John V; Lin DI; Danziger N; Pavlick DC; Elvin JA; Frimer M
JCO Precis Oncol; 2021; 5():. PubMed ID: 34585039
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
Abdel-Wahab R; Yap TA; Madison R; Pant S; Cooke M; Wang K; Zhao H; Bekaii-Saab T; Karatas E; Kwong LN; Meric-Bernstam F; Borad M; Javle M
Sci Rep; 2020 Dec; 10(1):22087. PubMed ID: 33328484
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.
Yakirevich E; Madison R; Fridman E; Mangray S; Carneiro BA; Lu S; Cooke M; Bratslavsky G; Webster J; Ross JS; Ali SM
Eur Urol Oncol; 2021 Apr; 4(2):282-288. PubMed ID: 31412008
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Moore JA; Chen KT; Madison R; Newberg JY; Fleischmann Z; Wang S; Sharaf R; Murugesan K; Fendler BJ; Hughes J; Schrock AB; Hegde PS; Oxnard GR; Fabrizio D; Frampton GM; Antonarakis ES; Sokol ES; Jin DX
JCO Precis Oncol; 2023 Sep; 7():e2300093. PubMed ID: 37769224
[TBL] [Abstract][Full Text] [Related]
15. Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
Necchi A; Cucchiara V; Grivas P; Bratslavsky G; Jacob J; Spiess PE; Sokol ES; Killian JK; Lin D; Ramkissoon S; Huang RSP; Madison RW; Venstrom JM; Schrock AB; Danziger N; Decker B; Gjoerup O; Graf RP; Oxnard GR; Tukachinsky H; Ross JS
Cancer; 2021 Dec; 127(24):4557-4564. PubMed ID: 34379803
[TBL] [Abstract][Full Text] [Related]
16. The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.
Tsantikidi A; Papadopoulou E; Metaxa-Mariatou V; Kapetsis G; Tsaousis G; Meintani A; Florou-Chatzigiannidou C; Gazouli M; Papadimitriou C; Timotheadou E; Kotsakis A; Boutis A; Boukovinas I; Kampletsas E; Kontovinis L; Fountzilas E; Andreadis C; Karanikiotis C; Filippou D; Theodoropoulos G; Özdoğan M; Nasioulas G
Diagnostics (Basel); 2023 Sep; 13(18):. PubMed ID: 37761329
[TBL] [Abstract][Full Text] [Related]
17. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
18. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
19. Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Landen CN; Molinero L; Hamidi H; Sehouli J; Miller A; Moore KN; Taskiran C; Bookman M; Lindemann K; Anderson C; Berger R; Myers T; Beiner M; Reid T; Van Nieuwenhuysen E; Green A; Okamoto A; Aghajanian C; Thaker PH; Blank SV; Khor VK; Chang CW; Lin YG; Pignata S
Clin Cancer Res; 2023 May; 29(9):1698-1707. PubMed ID: 36595569
[TBL] [Abstract][Full Text] [Related]
20. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]